Endocrine Abstracts

Many studies and treatment guidelines have emphasized that the treatment of DM extends beyond glycaemic control, but include lowering lipids, and blood pressure in people living with DM. According to The Task Force on Diabetes and Cardiovascular Disease of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD), dyslipidaemia is strongly related to increased CVD risk. This study determined the prevalence of dyslipidaemia in Type 2 DM patients attending the OAUTHC, Ile Ife South West Nigeria from January to November 2014.

Method: This cross-sectional descriptive study involved Three hundred (300) consecutive Type 2 diabetic presenting at OAUTHC, Ile-Ife. Relevant clinical information and physical examination was carried out. Venous blood was collected to determine total cholesterol, low density lipoprotein, high density lipoprotein and triglycerides. Lipid goals was based on total cholesterol <200 mg/dl, triglycerides <150 mg/dl, LDL <100 mg/dl and HDL <40 mg/dl in male and <50 mg/dl in female.

Results: A total of 300 type 2 Diabetes mellitus patients were recruited into the study. One hundred and three (35.3%) were males and 194 (64.7%) female. The mean age was 61.17+10.5 years with a mean age of 62.0+10.9 years for males and 60.7+10.3 years females respectively. Of the 300 participants, One hundred and eleven (37.0%) subjects achieved optimal lipid control while 187 (63.0%) of the study subjects had dyslipidaemia. 85 (28.3%) study participants had total cholesterol of >200 mg/dl, 115 (38.3%) with LDL cholesterol above 100 mg/dl and 24.7% with triglycerides of >150 mg/dl and 28.3% for HDL of <40 mg/dl in men and 50 mg/dl in women.

Conclusions: The proportion of patient with poor lipid goal was high. Adequate management of dyslipidaemia should be paramount in the management of type 2 diabetes patients.